Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts

Leukemia and Lymphoma

Volumn 46, Issue 2, 2005, Pages 257-263

  Cosenza, Maria ^a   Civallero, Monica ^a   Sacchi, Stefano ^a   Marcheselli, Raffaella ^a   Pozzi, Samantha ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Apoptosis; Arsenic trioxide; Atra; Cell cycle; Growth inhibition; Non M3 leukemic blasts

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BROXURIDINE; KI 67 ANTIGEN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SPECIFICITY; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

APOPTOSIS; ARSENICALS; BROMODEOXYURIDINE; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; KI-67 ANTIGEN; KINETICS; LEUKEMIA, MYELOCYTIC, ACUTE; OXIDES; S PHASE; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 13244289904     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400014991     Document Type: Article

References (46)

1. Huang ME, Ye YC, Chen SR, Chai Jr, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72(2):567-572.
2. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans-retinoic acid as a differentiating therapy for acute promyelocytic leukemia. Clinical results. Blood 1990;76(9):1704-1709.
3. Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri ML, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jacubowski A, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New England Journal of Medicine 1991;324(20): 1385-1393.
4. Tallman MS, Andersen JW, Appelbaum ASC, Appelbaum FR. All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine 1997;337(15):1021-1028.
5. Chen Z, Tong JH, Dong S, Zhu J, Wang ZY, Chen SJ. Retinoic acid regulatory pathways, chromosomal translocations; and acute promyelocytic leukemia. Genes Chromosomes and Cancer 1996;15(3):147-156.
6. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13(11):1881-1892.
7. Athanasiadis I, Kies MS, Miller M, Ganzenko N, Joob A, Marymont M, Rademaker A, Gradishar WJ. Phase II study of all-trans-retinoic acid and alfa-interferon in patients with advanced non-small cell lung cancer. Clinical Cancer Research 1995;1(9):973-979.
8. Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, Murphy RF, Cohen RB, Broder S, Yarchoan R. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a in patients with epidemic Kaposi's sarcoma. Journal of Clinical Oncology 1995;13(8):1966-1974.
9. Krupitza G, Hulla W, Dittrich E, Kallay E, Harant H, Huber H, Grunt T, Dittrich C. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. International Journal of Cancer 1995;61(5):649-657.
10. Massad LS, Turyk M, Bitterman EP, Wilbanks GD. Interferon-alfa and all-trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers. Gynecologic Oncology 1996;60(3):428-434.
11. Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E. All-trans-retinoic acid for treating germ cell tumors: in vitro activity and results of a phase II trial. Cancer 1995;76(4):680-686.
12. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG. Differential effects of N (4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Research 1995;55(4):853-861.
13. Mangiarotti R, Danova M, Alberici R, Pellicciari C. All-trans retinoic acid (ATRA) induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. British Journal of Cancer 1998;77(2):186-191.
14. Lehmann S, Bengtzen S, Broberg U, Paul C. Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML. Leukemia Research 2000;24(1):19-25.
15. Lishner M, Curtis JE, Minkin S, McCulloch EA. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. Leukemia 1989;3(11):784-788.
16. Yang GS, Minden MD, McCulloch EA. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 1994;8(12):2065-2075.
17. Zheng A, Savolainen ER, Koistinen P. All-trans retinoic acid induces apoptosis in acute myeloblastic leukaemia cells. Apoptosis 1997;2(3):319-329.
18. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89(9):3354-3360.
19. Wang Zhen-Hi. Arsenic compound as anticancer agents. Cancer Chemotherapy and Pharmacology 2001;48(Suppl 1):72-76.
20. Chen Z, Chen GQ, Shen ZY, Chen SY, Wang ZY. Treatments of acute promyelocytic leukemia with arsenic trioxide compound: in vitro and in vivo. Seminars in Hematology 2001;38(1):26-36.
21. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94(10):3315-3324.
22. Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanism of action. Seminars in Hematology 2002;39 (2 Suppl 1): 3-7.
23. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 of PML-RAR(/PML proteins. Blood 1996;88(3 ):1052-1061.
24. 3 exerts dose-dependent dual effects on APL cells. Blood 1997;89(9):3345-3353.
25. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine 1998;339(19):1341-1348.
26. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ochichi N, Yagi N. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activations of caspases and downregulation of bcl-2 protein. British Journal of Hematology 1998;102(4):1055-1060.
27. Konig A, Wrazel L, Warrel RP jr, Rivi R, Pandolfi PP, Jakubowski A, Gabrilove JL. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia cell lines. Blood 1997;90(2):562-570.
28. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinical achievable concentrations. Journal of National Cancer Institute 1999;91(9):772-778.
29. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Research 1999;59(5):1041-1048.
30. Puccetti E, Gullet S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Research 2000;60(13):3409-3413.
31. 3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. European Journal of Haematology 2001;66(6):357-364.
32. Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Medical Oncology 1999;16(1):58-64.
33. Gianni M, Koken MH, Chelbi-Alix AAK, Benoit G, Lanotte M, Chen Z, de The H. Combined arsenic trioxide and retinoic acid treatment enhances differentiation and apoptosis in arsenic resistant NB4 cells. Blood 1998;91(11):4300-4310.
34. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). Journal of Histochemistry and Cytochemistry 1984;32(2):219-229.
35. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93(8):2478-2484.
36. Venditti A, Tamburini A, Buccisano F, Scimo MT, Del Poeta G, Maurillo L, Cox MC, Abruzzese E, Tribalto M, Masi M, Amadori S. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Annals of Hematology 2000;79(3):138-142.
37. Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leukemia and Lymphoma 1999;35(5-6):483-489
38. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi S, Tamassia MG, Sacchi S. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 1995;80(2):98-102.
39. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Della Porta G. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992;79(5):1291-1298.
40. Davison K, Mann KK, Waxman S. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004;103(9):3496-3502.
41. Cai X, Yu Y, Huang Y, Zhang L, Jia PM. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003;17:1333-1337.
42. Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T, Know TK. Arsenic trioxide induces G2/M growth arrest and apoptosis after Caspase-3 activation and bcl-2 phospolylation in promonocytic U937 cells. Biochemical and Byophysical Research Communications 2001;286:726-738.
43. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Groenemeyer H. Retionic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Medicine 2001;7(6):680-686.
44. Lotan R. Effect of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochimica Biophysica Acta 1980;605(1):33-91.
45. 3) on non-acute promyelocytic leukemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. British Journal of Haematology 2002;116(3 ):555-563.
46. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101(15):5328-5335.